Humanigen Inc (HGENQ)

[LPF91]

If fda is concerned about jak inhibitors heart-related issues and blood clot issues can this decline be about the fact that Lenz showed higher cardiac arrest (8 patients for lenz (3%) vs 4 placebo (1.6%)) and higher pulmonary embolism (5 patients for Lenz (2.0%) vs 3 placebo (1.2%)) than placebo?

"FDA Drug Safety Podcast on required warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions"